Fasiha Kanwal1, Jennifer R Kramer, Jawad Ilyas, Zhigang Duan, Hashem B El-Serag. 1. Clinical Epidemiology and Outcomes Program, Houston VA Health Services Research and Development Center of Excellence, Center for Innovations in Quality, Effectiveness, and Safety (IQuESt), Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX; Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine and Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX.
Abstract
UNLABELLED: Data show that viral genotype 1 may increase the risk of cirrhosis and hepatocellular carcinoma (HCC) compared to genotype 2 in patients with chronic hepatitis C virus (HCV) infection. However, the effect of HCV genotype 3 on cirrhosis and HCC risk is uncertain. We identified patients with active HCV infection, confirmed by positive polymerase chain reaction (PCR) and a known HCV genotype, from the VA HCV Clinical Case Registry between 2000 and 2009. We examined the effect of HCV genotype on the risk of cirrhosis and HCC in a Cox proportional hazards model adjusting for patients' age, period of service (World War I/II, Vietnam era, post-Vietnam era), race, gender, human immunodeficiency virus (HIV) infection, alcohol use, diabetes, body mass index, and antiviral treatment receipt. Of the 110,484 patients with active HCV viremia, 88,348 (79.9%) had genotype 1, 13,077 (11.8%) genotype 2, 8,337 (7.5%) genotype 3, and 1,082 (0.9%) patients had genotype 4 infection. Despite being younger, patients with genotype 3 had a higher risk of developing cirrhosis (unadjusted hazard ratio [HR] = 1.40, 95% confidence interval [CI] = 1.32-1.50) and HCC (unadjusted HR = 1.66, 95% CI = 1.48-1.85) than HCV genotype 1 patients. After adjustment for prespecified demographic, clinical, and antiviral treatment factors, the risk of cirrhosis and HCC was 31% (adjusted HR = 1.31, 95% CI = 1.22-1.39) and 80% (adjusted HR = 1.80, 95% CI = 1.61-2.03) higher in patients with genotype 3 compared to genotype 1 infected patients. CONCLUSION: HCV genotype 3 is associated with a significantly increased risk of developing cirrhosis and HCC compared to HCV genotype 1. This association is independent of patients' age, diabetes, body mass index, or antiviral treatment.
UNLABELLED: Data show that viral genotype 1 may increase the risk of cirrhosis and hepatocellular carcinoma (HCC) compared to genotype 2 in patients with chronic hepatitis C virus (HCV) infection. However, the effect of HCV genotype 3 on cirrhosis and HCC risk is uncertain. We identified patients with active HCV infection, confirmed by positive polymerase chain reaction (PCR) and a known HCV genotype, from the VA HCV Clinical Case Registry between 2000 and 2009. We examined the effect of HCV genotype on the risk of cirrhosis and HCC in a Cox proportional hazards model adjusting for patients' age, period of service (World War I/II, Vietnam era, post-Vietnam era), race, gender, human immunodeficiency virus (HIV) infection, alcohol use, diabetes, body mass index, and antiviral treatment receipt. Of the 110,484 patients with active HCV viremia, 88,348 (79.9%) had genotype 1, 13,077 (11.8%) genotype 2, 8,337 (7.5%) genotype 3, and 1,082 (0.9%) patients had genotype 4 infection. Despite being younger, patients with genotype 3 had a higher risk of developing cirrhosis (unadjusted hazard ratio [HR] = 1.40, 95% confidence interval [CI] = 1.32-1.50) and HCC (unadjusted HR = 1.66, 95% CI = 1.48-1.85) than HCV genotype 1 patients. After adjustment for prespecified demographic, clinical, and antiviral treatment factors, the risk of cirrhosis and HCC was 31% (adjusted HR = 1.31, 95% CI = 1.22-1.39) and 80% (adjusted HR = 1.80, 95% CI = 1.61-2.03) higher in patients with genotype 3 compared to genotype 1 infectedpatients. CONCLUSION:HCV genotype 3 is associated with a significantly increased risk of developing cirrhosis and HCC compared to HCV genotype 1. This association is independent of patients' age, diabetes, body mass index, or antiviral treatment.
Authors: G Nkontchou; M Ziol; M Aout; M Lhabadie; Y Baazia; A Mahmoudi; D Roulot; N Ganne-Carrie; V Grando-Lemaire; J-C Trinchet; E Gordien; E Vicaut; I Baghad; M Beaugrand Journal: J Viral Hepat Date: 2011-10 Impact factor: 3.728
Authors: Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane Journal: N Engl J Med Date: 2013-04-23 Impact factor: 91.245
Authors: Ira M Jacobson; Stuart C Gordon; Kris V Kowdley; Eric M Yoshida; Maribel Rodriguez-Torres; Mark S Sulkowski; Mitchell L Shiffman; Eric Lawitz; Gregory Everson; Michael Bennett; Eugene Schiff; M Tarek Al-Assi; G Mani Subramanian; Di An; Ming Lin; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Keyur Patel; Jordan Feld; Stephen Pianko; David R Nelson Journal: N Engl J Med Date: 2013-04-23 Impact factor: 91.245
Authors: L Rubbia-Brandt; P Fabris; S Paganin; G Leandro; P-J Male; E Giostra; A Carlotto; L Bozzola; A Smedile; F Negro Journal: Gut Date: 2004-03 Impact factor: 23.059
Authors: Adriaan J van der Meer; Bart J Veldt; Jordan J Feld; Heiner Wedemeyer; Jean-François Dufour; Frank Lammert; Andres Duarte-Rojo; E Jenny Heathcote; Michael P Manns; Lorenz Kuske; Stefan Zeuzem; W Peter Hofmann; Robert J de Knegt; Bettina E Hansen; Harry L A Janssen Journal: JAMA Date: 2012-12-26 Impact factor: 56.272
Authors: Martin Lagging; Galia Askarieh; Francesco Negro; Stephanie Bibert; Jonas Söderholm; Johan Westin; Magnus Lindh; Ana Romero; Gabriele Missale; Carlo Ferrari; Avidan U Neumann; Jean-Michel Pawlotsky; Bart L Haagmans; Stefan Zeuzem; Pierre-Yves Bochud; Kristoffer Hellstrand Journal: PLoS One Date: 2011-02-24 Impact factor: 3.240
Authors: Magdalena Ydreborg; Johan Westin; Karolina Rembeck; Magnus Lindh; Hans Norrgren; Anna Holmberg; Rune Wejstål; Gunnar Norkrans; Kristina Cardell; Ola Weiland; Martin Lagging Journal: PLoS One Date: 2013-11-14 Impact factor: 3.240
Authors: Myrna L Cozen; James C Ryan; Hui Shen; Ramsey Cheung; David E Kaplan; Christine Pocha; Norbert Brau; Ayse Aytaman; Warren N Schmidt; Marcos Pedrosa; Bhupinderjit S Anand; Kyong-Mi Chang; Timothy Morgan; Alexander Monto Journal: Dig Dis Sci Date: 2016-04-08 Impact factor: 3.199
Authors: Mei-Hsuan Lee; Tiffany I Hsiao; Shreenidhi R Subramaniam; An K Le; Vinh D Vu; Huy N Trinh; Jian Zhang; Mingjuan Jin; Vincent Wai-Sun Wong; Grace Lai-Hung Wong; Mindie H Nguyen Journal: Am J Gastroenterol Date: 2017-04-25 Impact factor: 10.864